Geert A. Nibourg
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: December 15, 2012
Increased hepatic functionality of the human hepatoma cell line HepaRG cultured in the AMC bioreactor.
Journal: The international journal of biochemistry & cell biology
Published: December 06, 2012
Physiological and biochemical basis of clinical liver function tests: a review.
Journal: Annals of surgery
Published: July 28, 2012
Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-bioartificial liver.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: July 04, 2012
Proliferative human cell sources applied as biocomponent in bioartificial livers: a review.
Journal: Expert opinion on biological therapy
Published: June 02, 2012
The effect of rat acute-liver-failure plasma on HepaRG cells.
Journal: The International journal of artificial organs
Published: May 23, 2012
Perfusion flow rate substantially contributes to the performance of the HepaRG-AMC-bioartificial liver.
Journal: Biotechnology and bioengineering
Published: March 16, 2012
Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure.
Journal: PloS one
Published: January 30, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026